XORTX Therapeutics Inc.
XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.
XORTX Therapeutics Inc. (XRX)
SEDAR Information
Company Info
Capitalization
Company Officers
Bulletins
2021-1109 - Delist - XORTX Therapeutics Inc. (XRX)
le 4 novembre/November 2021
At the request of the company the common shares of XORTX Therapeutics Inc. will be delisted at market close on November 4, 2021.
The Company’s common shares will continue to trade on the TSX Venture Exchange.
___________________________
À la demande de la société, les actions ordinaires de XORTX Therapeutics Inc. seront radiées à la clôture du marché le 4 novembre 2021.
Les actions ordinaires de la Société continueront d'être négociées à la Bourse de croissance TSX.
